Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Price | 1784€+ Login to see price |
Organism | Human |
Product Type | Organoid |
Tissue | Hepatocellular carcinoma, Total necrotic lesion |
Disease | Hepatocellular carcinoma |
Applications
Oncology
Small Molecule
Antibody
Cancer Vaccine
mRNA
Immune Cell
TME-CAF
Immuno Oncology
Macrophage
Regulatory T Cell
Tumor-Infiltrating Lymphocyte
Cytotoxic T Cell
The hepatocellular carcinoma (HCC) organoids we create exhibit the same marker expression patterns, such as AFP positivity, CK19 negativity, and HepPar1 positivity, as the patient tissues they are derived from.
These organoids can be utilized for personalized drug testing, disease modeling, and biomarker discovery, ensuring that therapeutic strategies are tailored to the specific characteristics of each patient’s tumor.
We provide a valuable platform for developing and testing targeted therapies and studying tumor microenvironment interactions.
H&E | AFP | CK19 | EpCAM | HepPar 1 | |
|---|---|---|---|---|---|
Cancer tissue |  |  |  |  |  |
Cancer organoid |  |  |  |  |  |
Our histological analysis demonstrated that the organoids faithfully replicated the expression patterns of critical markers AFP, CK19, EpCAM, and HepPar1 found in the original tissues.
This alignment proves the efficacy of our organoids for precise disease modeling and medical research, paving the way for targeted therapeutic applications and biomarker discovery.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
